Histone modifications as a platform for cancer therapy
Open Access
- 18 February 2005
- journal article
- review article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 94 (6) , 1088-1102
- https://doi.org/10.1002/jcb.20387
Abstract
Tumorigenesis and metastasis are a progression of events resulting from alterations in the processing of the genetic information. These alterations result from stable genetic changes (mutations) involving tumor suppressor genes and oncogenes (e.g., ras, BRAF) and potentially reversible epigenetic changes, which are modifications in gene function without a change in the DNA sequence. Mutations of genes coding for proteins that directly or indirectly influence epigenetic processes will alter the cell's gene expression program. Epigenetic mechanisms often altered in cancer cells are DNA methylation and histone modifications (acetylation, methylation, phosphorylation). This article will review the potential of these reversible epigenetic processes as targets for cancer therapies.Keywords
This publication has 110 references indexed in Scilit:
- DNA demethylation and cancer: therapeutic implicationsCancer Letters, 2004
- Cancer genes and the pathways they controlNature Medicine, 2004
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004
- The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3Published by Elsevier ,2004
- Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPKNature Cell Biology, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- Solvent Mediated Interactions in the Structure of the Nucleosome Core Particle at 1.9Å ResolutionJournal of Molecular Biology, 2002
- Molecular mechanisms underlying ErbB2/HER2 action in breast cancerOncogene, 2000
- Control of Chromatin RemodelingCritical Reviews™ in Eukaryotic Gene Expression, 2000
- Genetic pathways in colorectal and other cancersEuropean Journal Of Cancer, 1999